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Abstract
Aims CORE is a continuing medical education initiative designed to support the evidence-based management of heart failure
(HF) in the primary and secondary care settings. The goal of the CORE Needs Assessment Survey is to describe current clinical
practice patterns and attitudes among global stakeholders in HF care.
Methods and results The CORE Steering Committee guided the development of survey questions to assess clinical practice,
conﬁdence, and attitudes/perceptions among cardiologists, primary care physicians, and nurses involved in HF management.
In total, 346 healthcare professionals from Australia (n = 59), Austria (n = 59), Canada (n = 60), Spain (n = 58), Sweden (n = 52),
and the UK (n = 58) contributed survey data. Results revealed multiple gaps over the spectrum of HF care, including diagnosis
(low recognition of the signs and symptoms of HF and limited use of diagnostic tests), treatment planning (underuse of rec-
ommended agents and subtherapeutic dosing), treatment monitoring and adjustment (lack of adherence to recommenda-
tions), and long-term management (low conﬁdence in providing patient education). Although primary care and specialist
physicians and nurses shared common unmet needs, healthcare professional-speciﬁc clinical gaps were also identiﬁed.
Conclusions The CORE Needs Assessment Survey provides timely data describing current clinical practices and attitudes
among physicians and nurses regarding key aspects of HF care. These ﬁndings will be useful for guiding the development of
interventions tailored to the speciﬁc educational needs of different provider types and designed to support the evidence-
based care of patients with HF.
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Introduction
Heart failure (HF) is associated with frequent hospitalizations,
high morbidity and mortality rates, and enormous healthcare
costs.1 Moreover, given the ageing population and prolonged
survival of patients with cardiovascular disease, the preva-
lence and public health burden of HF are expected to grow.2
Therefore, the effective diagnosis and treatment of patients
with HF are essential.3,4 However, many patients with HF
are not receiving treatments and/or appropriate doses that
demonstrate beneﬁt in clinical trials and are not receiving
care within a multidisciplinary framework that emphasizes
effective long-term management.5–7
Continuing medical education supports the improve-
ment of knowledge, conﬁdence, and clinical performance
among healthcare providers (HCPs).8 CORE is an ongoing
continuing medical education initiative, designed to en-
hance the delivery of evidence-based care in HF by in-
creasing prompt HF diagnosis, improving the use of
appropriate interventions, improving disease management
through better comorbidity competence, and increasing
multidisciplinary collaboration and communication across
the wider HF care team.
The current analysis of the CORE Needs Assessment Survey
aims to (i) document practice and conﬁdence gaps in HF
management by HCP type and (ii) inform educational
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any me-
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interventions for cardiologists, primary care physicians
(PCPs), and nurses involved in HF management.
Methods
The CORE Needs Assessment Survey was conducted in
English or the local languages as speciﬁed among primary
and secondary care HCPs who manage patients with HF in
six countries: Australia, Austria (German), Canada, Spain
(Spanish), Sweden (Swedish), and the UK. The survey was
conducted online by PCM Scientiﬁc in collaboration with
Doctors.net.UK, a third-party professional body.
Survey design
The survey was designed to assess key areas of HF knowledge
and clinical practice based on the 2012 European Society of
Cardiology (ESC) guidelines.3 Survey questions were devel-
oped from a literature review, preliminary needs assessment,
and expert opinion and then reviewed and approved by the
international and multidisciplinary CORE Steering Committee
members (Appendix 1). The survey used a range of question
formats to measure conﬁdence, clinical practice patterns,
and attitudes/perceptions related to the diagnosis, treat-
ment, monitoring, long-term management, and multidisci-
plinary care of patients with HF. Given variations across
national HF guidelines, care was taken not to assess ideas
or practices that differed by country.9,10
Participating cardiologists and PCPs were recruited from
online HCP panels (Austria, Australia, Canada, Spain, and
UK) and/or telephone databases (Austria, Australia, Canada,
and Sweden), and nurses were recruited via telephone. Only
those who met the screening requirements were invited to
complete the country-speciﬁc online surveys. All survey re-
spondents received a small honorarium in accordance with
legal and ethical guidelines from the British Healthcare Busi-
ness Intelligence Association.11
To assess self-reported conﬁdence in clinicians’ knowledge
and practice decisions, respondents were asked to rank their
conﬁdence on the following 7-point scale: 1–2 (not at all con-
ﬁdent), 3–5 (mid-conﬁdence), and 6–7 (very conﬁdent).
Statistical analysis plan
The statistical analysis includes only complete surveys; no re-
sponses were lost or missing. Data are presented as aggre-
gate mean percentage responses among respondents from
all geographic regions. The Student’s t-test and analysis of
variance were used to detect differences between HCP co-
horts (signiﬁcance cut-off, P < 0.005). No survey questions
were excluded because of unusually high or low ‘correct’ re-
sponses rates.
The primary objective is to deﬁne global trends in HF
knowledge, conﬁdence, and practice among cardiologists,
PCPs, and cardiac and primary care nurses. Secondary objec-
tives are to detect variations across national ﬁndings; these
data will be reported elsewhere.
Results
Respondents
In total, 944 HCPs replied to requests to participate (i.e.
clicked on the online survey link), and 346 (37%) completed
the survey. The percentage of HCPs who completed surveys
varied from 32% to 75% by country: Australia (59/176;
33%), Austria (59/88; 67%), Canada (60/145; 41%), Spain
(58/183; 32%), Sweden (52/106; 49%), and UK (58/77;
75%). Respondents included 65 cardiologists, 160 PCPs, 50
cardiac nurses, and 71 primary care nurses (Table 1).
Physicians’ attitudes and practice patterns
Key survey questions and responses among both cardiologists
and PCPs are summarized in Tables 2–4.
Diagnosis
Among 22 symptoms and signs of HF, just 11 (50%) were rou-
tinely assessed and considered to be HF markers by ≥90% of
physicians. In particular, fewer than 50% of cardiologists and
PCPs routinely assessed or considered the following as
markers of HF: forgetfulness, confusion, and sputum (Table 2).
When asked about diagnostic tests, many PCPs did not
consider echocardiography (34%), ECG (39%), or laboratory
tests (59%) to be essential for HF diagnosis. Approximately
one-third of PCPs (32%) reported that performing or provid-
ing a referral for echocardiography was not relevant to their
role in patient management (Table 2).
In terms of diagnostic conﬁdence, cardiologists reported
high levels of conﬁdence (≥70% scoring 6–7) in identifying a
number of aspects of HF diagnosis (Figure 1); they were rela-
tively less conﬁdent in diagnosing HF with preserved ejection
fraction (HF-PEF) and providing patient education. Although
Table 1 CORE Needs Assessment respondent demographics
Total Cardiologist
Primary care
physician
Cardiac
nurse
Primary care
nurse
Australia 59 12 26 8 13
Austria 59 12 26 8 13
Canada 60 10 29 8 13
Spain 58 10 26 9 13
Sweden 52 11 27 8 6
UK 58 10 26 9 13
Total 346 65 160 50 71
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PCPs were most conﬁdent in identifying atrial ﬁbrillation,
<70% scored 6–7 for any other aspect of diagnosis. Notably,
PCPs were least conﬁdent in the following aspects: diagnos-
ing HF-PEF, diagnosing HF with reduced ejection fraction
(HF-REF), and providing patient education relevant to HF di-
agnosis and management.
Treatment
Physicians reported high rates of using diuretics (94–100%),
angiotensin-converting enzyme (ACE) inhibitors (99–100%),
and beta-blockers (97–99%) in patients with HF (Table 3).
The use of mineralocorticoid receptor antagonists (MRAs)
was slightly lower (88–94%). Although prescribing rates for
indicated agents were high, dosing was often inconsistent
with guideline recommendations.
Physicians were generally less conﬁdent in aspects of non-
pharmacological interventions compared with pharmacologi-
cal treatments. Of note, when asked about identifying
patients suitable for cardiac resynchronization therapy,
implantable cardiac deﬁbrillator, left ventricular assist
devices, or heart transplant, 38–82% of cardiologists and
9–14% of PCPs described themselves as ‘very conﬁdent’.
Monitoring
The survey results revealed that among physicians, a lower
proportion (54–64%) reported being involved in patient
monitoring after each dose increment or at the end of
medication compared with during treatment initiation
(71.9–86.2%; Table 4).
Table 2 Heart failure diagnosis practices among physicians and nurses
Cardiologists
(n = 65)
PCPs
(n = 160)
Cardiac nurses
(n = 50)
Primary care nurses
(n = 71)
Diagnosis
Symptoms and signs: In your clinical practice, which of the following indicators do you routinely assess or consider as speciﬁc or
non-speciﬁc markers for HF?
Abdominal bloating (%) 53.8 41.9 58.0 43.7
Ankle swelling (%) 96.9 98.8 98.0 93.0
Anorexia (%) 58.5 44.4 44.0 40.8
Breathlessness on exertion (%) 98.5 98.8 100 97.2
Chest pain (%) 67.7 80.6* 94.0 93.0
Chronic cough (%) 64.6 84.4* 84.0 76.1
Confusion (%) 36.9 35.6 52.0 43.7
Displaced apex beat (%) 76.9* 57.5 54.0 53.5
Dizziness (%) 58.5 60.0 74.0 73.2
Elevated jugular venous pressure (%) 95.4* 84.4 88.0** 69.0
Fatigue (%) 95.4* 87.5 90.0 87.3
Forgetfulness (%) 13.8 21.9 34.0 28.2
Heart murmur (%) 87.7 78.8 70.0 64.8
Nocturia (%) 58.5 53.8 54.0 54.1
Orthopnoea (%) 96.9 93.8 88.0 78.9
Palpitations (%) 75.4 65.6 84.0 78.9
Paroxysmal nocturnal dyspnoea (%) 96.9 95.0 86.0 74.6
Pulmonary crackles (%) 96.9 97.5 84.0 74.6
Reduced exercise tolerance (%) 96.9 96.3 88.0 90.1
Sputum (%) 30.8 40.6 56.0 45.1
Tachycardia (%) 95.4* 81.3 94.0 85.9
Third heart sound (%) 90.8* 73.1 62.0 49.3
Essential diagnostic tests: When assessing patients for suspected HF, which of the following do you carry out or refer the patient for?
Assessment of medical history, comorbidities, and current
medications (%)
83.1 75.6 78.0 77.5
Assessment of signs and symptoms (%) 83.1 76.3 76.0 80.3
Chest X-ray (%) 67.7 75.6 48.0 59.2
Coronary angiography (%) 56.9* 33.8 42.0 38.0
CT angiography (%) 38.5 28.1 40.0 25.4
Echocardiogram (%) 81.5 75.0 64.0 39.4
Electrocardiogram (%) 80.0 71.9 70.0 60.6
Fasting glucose and lipid level (%) 67.7 70.6 72.0 71.8
Lab tests for renal function, electrolytes, and to detect
comorbidity (%)
75.4 81.3 72.0 69.0
Liver function tests (%) 69.2 71.3 64.0 69.0
Renal function and electrolytes (%) 73.8 78.8 68.0 67.6
Serum natriuretic peptides (%) 70.8 59.4 58.0 47.9
Spirometry (%) 44.6 41.9 48.0 63.4
Thyroid function tests (%) 66.2 65.6 46.0 63.4
CT, computed tomography; HF, heart failure; PCP, primary care physician.
*Signiﬁcant difference (P < 0.005) between physician groups.
**Signiﬁcant difference (P < 0.005) between nurse groups.
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Regarding medication-speciﬁc monitoring, only 76% of
cardiologists and 68% of PCPs reported serial monitoring of
serum electrolytes in patients prescribed MRAs. In addition,
<70% of physicians reported monitoring blood chemistry
(creatinine and potassium) 1–2 weeks after initiating ACE
inhibitors and 1–2 weeks after ﬁnal dose titration. Only 58%
of cardiologists and 57% of PCPs reported monitoring blood
chemistry 1–2 weeks after initiating or dose-titrating diuretic
therapy.
Long-term management
More than 85% of cardiologists and PCPs routinely screened
HF patients for angina and hypertension. By comparison,
<60% reported screening HF patients for other comorbidities
including asthma, cancer, cognitive impairment, cachexia,
depression/anxiety, or gout (Table 4). In both physician
groups, few respondents reported being ‘very conﬁdent’ in
managing HF in the presence of a number of other commonly
co-occurring conditions: for PCPs, this was particularly
evident in patients with cancer, cerebrovascular disease,
Alzheimer’s disease or dementia, and cachexia (23–34%, ‘very
conﬁdent’); for cardiologists, this was true for anxiety, cancer,
Alzheimer’s disease or dementia, cachexia, and depression
(18–35%, ‘very conﬁdent’).
Regarding end-of-life (EOL) care, the majority of physicians
acknowledged the potential beneﬁts of EOL care among HF
patients who are clinically judged to be close to the end of life
(88–92%), who have a very poor quality of life (83%), and who
undergo frequenthospital admissions (77–80%;Table 4).Many
cardiologists and PCPs (13–23%) reported they were not
involved in the management of HF patients during EOL care.
Physicians reported substantial gaps related to HF patient
education, with a large portion of clinicians (25–56%) ‘rarely’
or ‘never’ discussing advanced care, the role of the caretaker,
Table 3 Heart failure treatment practices among physicians
Cardiologists
(n = 65)
PCPs
(n = 160)
Cardiac nurses
(n = 50)
Primary care
nurses (n = 71)
Treatment
Physician prescribing habits: Which of the following medications/classes do you routinely prescribe with regard to your patients
with HF?
ACE inhibitors (%) 99.4 100*
ARBs (%) 93.1 89.2
Beta-blockers (%) 96.9 98.5*
Digoxin (%) 56.9 58.5
Diuretics (%) 100* 93.8
Ivabradine (%) 17.5 57.0
MRAs (%) 94 88
Nitrates (%) 51.2 41.5
Dosing practices: For each of the following medication classes, please indicate the medication you use most often and the mean
total initiation and target daily doses that you prescribe of that speciﬁc medication.
ACE inhibitors
Ramipril (%) 63 34
Average startingdose (mg/day) (ESC recommendation: 2.5mg/day) 4.3 4.6
Mean target dose (mg/day) (ESC recommendation: 10 mg/day) 10.8 10.3
ARBs
Candesartan (%) 54 22.5
Average starting dose (mg/day) (ESC recommendation: 4–
8 mg/day)
6.9 11
Mean target dose (mg/day) (ESC recommendation: 32 mg/day) 27.4 27.1
Losartan (%) — 27
Average starting dose (mg/day) (ESC recommendation: 50 mg/
day)
— 39.4
Mean target dose (mg/day) (ESC recommendation: 150 mg/
day)
— 76.1
MRAs
Eplenerone (%) 22 —
Average starting dose (mg/day) (ESC recommendation: 25 mg/
day)
24.1 —
Mean target dose (mg/day) (ESC recommendation: 50 mg/day) 39.3 —
Spironolactone (%) 15 11
Average starting dose (mg/day) (ESC recommendation: 25 mg/
day)
22.5 37.5
Mean target dose (mg/day) (ESC recommendation: 25–50 mg/
day)
40 80.6
ACE, angiotensin-converting enzyme; ARBs, angiotensin receptor blockers; ESC, European Society of Cardiology; HF, heart failure; MRAs,
mineralocorticoid receptor agonists; PCP, primary care physician.
*Signiﬁcant difference (P < 0.005) between physician groups.
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psychological health, prognosis, self-care, sexual activity, and
travel/leisurewith their patients.Relative tocardiologists, PCPs
were more likely to discuss HF aetiology with their patients.
Neither primary care nor specialist HCPs were conﬁdent in
the referral process; PCPs expressed difﬁculty in following
guidelinesand localprocedures for this (47%and49% ‘verycon-
ﬁdent’, respectively), and just 29% of cardiologists were ‘very
conﬁdent’ transferringpatients toprimary care (seeSupporting
Information, Figure S1). PCPs expressed uncertainty around re-
ferring HF patients to secondary care, as well as low expecta-
tions that adequate handover information will be supplied
when HF patients are transferred back into primary care. By
comparison, cardiologists reporteda lackof conﬁdence thatpa-
tients would be managed effectively in primary care, with 58%
citing the lack of sufﬁcient primary care resources as a cause for
concern (see Supporting Information, Figure S1).
Nurses’ attitudes and practice patterns
Diagnosis
Nurses, particularly primary care nurses, perceived many
aspects of diagnosis as ‘not relevant’ to their role. In total,
<70% of primary care nurses assessed the following signs
and symptoms of HF: third heart sound, excess sputum,
nocturia, heart murmur, forgetfulness, elevated jugular
pressure, displaced apex beat, confusion, anorexia, and
abdominal bloating (Table 2). Additionally, 50% of cardiac
nurses and 58% of primary care nurses considered echo-
cardiography to be outside of their scope of practice. Re-
garding diagnostic conﬁdence, of all aspects of diagnosis
(Figure 2), primary care nurses were least conﬁdent in di-
agnosing HF-REF and HF-PEF (15%, ‘very conﬁdent’). How-
ever, it is noteworthy that 37–38% of primary care
Table 4 Heart failure monitoring and management practices among physicians and nurses
Cardiologists
(n = 65)
PCPs
(n = 160)
Cardiac nurses
(n = 50)
Primary care
nurses (n = 71)
Monitoring
Involvement in medication monitoring: At which of the following stages, if any, are you involved in monitoring patients taking
pharmacotherapy?
Initiation (%) 86.2* 71.9 68.0 52.1
After each dose increment (%) 55.4 63.8 66.0** 35.2
At end of medication (%) 53.8 56.9 44.0** 19.7
None (%) 1.5 0.6 4.0 19.7**
Long-term management
Screening for other conditions: Which of the following cardiovascular and non-cardiovascular conditions do you routinely screen
for speciﬁcally with regard to your HF patients?
Angina (%) 87.7 91.3 90.0 78.9
Anaemia (%) 84.6 83.8 62.0 46.5
Asthma (%) 49.2 46.9 38.0 46.5
Cancer (%) 12.3 16.9 8.0 12.7
Cognitive impairment (%) 24.6 38.1* 44.0 31.0
Cachexia (%) 46.2 36.3 30.0 31.0
COPD (%) 66.2 60.0 54.0 56.3
Diabetes mellitus (%) 84.6 85.0 64.0 59.2
Depression and anxiety (%) 32.3 52.5* 56.0 46.5
Hypertension (%) 96.4 96.9 92.0 94.4
Hyperuricaemia and gout (%) 33.8 44.4 24.0 25.4
Obesity (%) 63.1 73.8 56.0 70.4
Renal dysfunction (%) 87.7 93.8 75.0 66.2
Thyroid disease (%) 64.6 78.1* 42.0 47.9
Recognizing end of life beneﬁts: Of the following cases, which do you consider indicates that the patient might beneﬁt from
end-of-life care?
Cardiac cachexia (%) 87.7 80.6 36.0 45.1
Clinically judged to be close to the end of life (%) 87.7 90.6 92.0 91.5
Communication barrier (%) 16.9 10.0 12.0 16.9
Continued high levels of serum natriuretic peptides (BNP/NT-proBNP) (%) 23.1 16.3 10.0 19.7
Dependence in most activities of daily living (%) 61.5 58.1 50.0 53.5
Frequent admission to hospital or other serious episodes of decompensation,
despite exhausting all treatment options (%)
76.9 80.0 70.0 70.4
Low serum albumin (%) 35.4* 21.3 10.0 9.9
Low serum sodium (%) 44.6* 14.4 12.0 9.9
Symptoms at rest, and heart transplantation and mechanical circulatory support
ruled out (%)
83.1 72.5 66.0 54.9
Treatment failure at tertiary centre (%) 60.0 77.5* 60.0 71.8
Very poor quality of life (%) 83.1 82.5 68.0 85.9**
BNP/NT-proBNP, brain natriuretic peptide/N-terminal pro-brain natriuretic peptide; COPD, chronic obstructive pulmonary disease; PCP,
primary care physician.
*Signiﬁcant difference (P < 0.005) between physician groups.
**Signiﬁcant difference (P < 0.005) between nurse groups.
176 J. Howlett et al.
ESC Heart Failure 2018; 5: 172–183
DOI: 10.1002/ehf2.12205
nurses considered diagnosing HF-REF or HF-PEF to be not
relevant to their role. Cardiac nurses were also least conﬁ-
dent in diagnosing HF-REF (38%, ‘very conﬁdent’) and HF-
PEF (30%, ‘very conﬁdent’) relative to the other aspects
of diagnosis (identiﬁcation of atrial ﬁbrillation, left bundle
branch block, right bundle branch block, and left
ventricular hypertrophy and providing individualized
patient education).
Figure 1 Conﬁdence gaps in heart failure (HF) diagnosis among physicians. Cardiologists and primary care physicians (PCPs) were asked: ‘How conﬁ-
dent are you in carrying out each of the following aspects of HF diagnosis on a scale of 1 to 7, where 1 is not at all conﬁdent and 7 is very conﬁdent?’
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Figure 2 Conﬁdence gaps in heart failure (HF) diagnosis among nurses. Cardiac and primary care (PC) nurses were asked: ‘How conﬁdent are you in
carrying out each of the following aspects of HF diagnosis on a scale of 1 to 7, where 1 is not at all conﬁdent and 7 is very conﬁdent?’
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Monitoring
In general, nurses’ involvement with patient monitoring was
lower than that of physicians at all stages of HF management
(Table 4). However, cardiac nurses were more involved than
primary care nurses, particularly after each dose increment
(66% vs. 35%; P < 0.005) and at the end of medication
(44% vs. 20%; P < 0.005). Furthermore, cardiac nurses were
signiﬁcantly less likely than primary care nurses to report
not being involved in patient monitoring at all (4% vs. 20%;
P < 0.005).
Long-term management
Compared with physicians, nurses were less likely than physi-
cians to recognize several clinical features that indicate that
an HF patient might beneﬁt from EOL care, including cardiac
cachexia, low serum albumin and sodium, and having symp-
toms at rest (Table 4). In addition, a substantial proportion
of nurses (20% cardiac nurses and 30% primary care nurses)
reported that they were not involved in the management of
HF patients during EOL care (see Supporting Information,
Table S1).
Notable differences between primary and
secondary care
Substantial differences in practice and knowledge are antici-
pated between primary care HCPs and those who possess
specialist training in cardiology. Nonetheless, it is of some
interest to understand where appreciable differences exist
between the two groups. The most notable differences are
summarized in Supporting Information, Tables S2 and S3.
Initial observations of differences between
countries
Although a full analysis of national differences is reserved for
future analyses, a primary review of these data highlighted
some interesting differences between countries, which we
plan to expand upon in future work.
With respect to diagnostic tests, there was variation in the
use of several key diagnostic tests. The use of natriuretic pep-
tides was lowest in Australia (44%) and highest in the UK
(71%); spirometry use was lowest in the UK (38%) and highest
in Canada (58%), and the use of chest X-ray was lowest in
Sweden (42%) and highest in Australia and the UK (76%; data
on ﬁle). We suspect this reﬂects heterogeneity of test avail-
ability and access in each of the countries, as well as some
differences between national guidelines. For example, at
the time of issuing the survey, natriuretic peptide testing
was not a routine practice in Australian guidelines and has
only recently been considered preferable (an essential when
echocardiogram is unavailable).
With respect to prescribing habits, cardiologists from the
UK and Canada generally prescribed most medication classes
less frequently than cardiologists from all other countries.
Notably, angiotensin receptor blockers, diuretics, and MRAs
were routinely prescribed by <80% of cardiologists in the
UK and Canada, whereas this was 100% by cardiologists in
all other countries. Of note, beta-blockers were routinely pre-
scribed by 90% of cardiologists in Canada, compared with
100% in all other countries (data on ﬁle). Again, without
further analysis, we can only attribute this to differences in
medication availability at this point.
Finally, with respect to patient referral practices, all
countries displayed a moderate degree of conﬁdence with
following local procedures, following local guidelines and
identifying patients who require referral to secondary care
(average conﬁdence level 5.5 out of 7), with the exception
of Austria. Austria displayed notably lower conﬁdence
(average conﬁdence 3.5 out of 7; data on ﬁle).
Discussion
To date, multiple studies have identiﬁed gaps and challenges
in modern HF care focused on speciﬁc provider types and
geographic regions.5–7,12–23 The CORE Needs Assessment Sur-
vey adds to the evidence base by describing practice patterns
across primary care and specialist physicians and nurses using
the same instrument. By including HCPs from multiple conti-
nents, the CORE Needs Assessment Survey provides a more
global insight on HF practice trends. Findings from the survey
will be useful for tailoring educational interventions to ad-
dress knowledge and practice gaps in the following key areas:
HF diagnosis, treatment planning, treatment monitoring and
adaptation, long-term management, and multidisciplinary
care in HF.
Addressing gaps in heart failure diagnosis
The accurate and timely diagnosis of HF is critical for guiding
appropriate treatment,3,4 yet diagnostic tests are
underutilized by many clinicians, as evidenced in the Study
on Heart failure Awareness and Perception Europe and
EuroHeart Failure Survey.5,6 In primary care, reluctance to
use certain tests, including echocardiography, may be due
to lack of knowledge about how to interpret results.18
In the present study, clinicians reported considering just
half of all symptoms and signs of HF. Therefore, there is a
need to raise awareness about the importance of assessing
less speciﬁc symptoms and signs (e.g. confusion or dizzi-
ness). Case studies are an ideal format for reinforcing best
practices around the diagnostic assessment of patients with
suspected HF.
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Among diagnostic tests for HF, PCPs and nurses re-
ported low conﬁdence in carrying out and interpreting
the results of echocardiography, and nurses were unlikely
to carry out or refer patients for echocardiography, ECG,
and laboratory tests. It should be noted that, depending
on local procedures, such activities may lie outside of
the professional remit of some nurses, although, regard-
less of this, nurses and PCPs would beneﬁt from tailored
education that reviews when to order these tests and
how to interpret the results.
Only cardiologists were conﬁdent in their diagnostic skills
related to HF-REF, and all HCP cohorts were least conﬁdent
in diagnosing HF-PEF. Educational interventions designed to
address gaps in HF diagnosis should focus on all HF sub-
types to reinforce baseline knowledge on HF-PEF and im-
prove knowledge and conﬁdence around the diagnosis of
HF-REF.
Many PCPs and primary care nurses—and, to a lesser
extent, cardiac nurses—expressed a lack of conﬁdence
in providing patient education at the time of HF diagno-
sis. Others reported that HF patient education was not
part of their role as a member of the HF care team.
However, the ESC guidelines emphasize the critical role
of patient education is supporting optimal patient out-
comes.3 To enhance conﬁdence around patient education,
PCPs, primary care nurses, and cardiac nurses would ben-
eﬁt from a checklist of key patient education topics, as
well as practical tools for improving patient/HCP
communication.
Addressing gaps in treatment planning
In the Study on Heart failure Awareness and Perception
Europe and EuroHeart Failure studies, effective ﬁrst-line
medications were underutilized and/or prescribed at
subtherapeutic doses in many patients with HF.5,6 The CORE
survey provides a current snapshot of prescribing practices
on a global level and suggests that cardiologists and PCPs
appeared to prescribe diuretics, MRAs, and other common
HF medications at rates and/or doses that are inconsistent
with guideline recommendations. Although the underlying
reasons driving these prescribing patterns are unclear, these
ﬁndings support the need for education reinforcing
evidence-based dosing, titration, indications, and sequencing
of HF medications, with an emphasis on diuretics, MRAs, ACE
inhibitors, angiotensin receptor blockers, and beta-blockers.
Clinicians would beneﬁt from detailed guidance on
identifying appropriate HF patients for non-pharmacological
interventions.
Both cardiac and primary care nurses infrequently engaged
with patients about pharmacological treatment, highlighting
the presence of barriers in this aspect of patient education.
Nurses may beneﬁt from an educational intervention that
models effective patient education around basic HF
treatment options.
Addressing gaps in treatment monitoring and
adaptation
Poor patient monitoring is a widespread barrier to better HF
care: in the UK, only half of NHS organizations had institu-
tional protocols that met minimum requirements regarding
patient monitoring13 and across Europe, only seven of 26
countries surveyed reported having organized protocols for
HF patient monitoring in more than 30% of their hospitals.14
In the present study, medication monitoring emerged as
an area with a high degree of variability in knowledge and
conﬁdence across respondent cohorts. These ﬁndings sup-
port an educational strategy that provides context around
monitoring requirements from a treatment-pathway perspec-
tive, for example, what tests should be carried out and when
for patients receiving an ACE inhibitor. This provides a practi-
cal addition to reviewing abstract concepts related to blood
pressure, heart rhythm, and serum marker monitoring. Of
note, all HCP groups tended to monitor patients less fre-
quently after each dose increment and at the end of treat-
ment, with a substantial minority of primary care nurses
reporting that they were not involved in patient monitoring
at any stage. These ﬁndings highlight the need for a ‘best
practice’ section that includes a checklist for each HCP group
to raise awareness of the importance of medication monitor-
ing at each HF treatment stage.
Respondents demonstrated variable levels of conﬁdence
related to the management of patients with cardiac and
non-cardiac comorbidities, highlighting the importance of
reviewing all comorbid conditions, with an emphasis placed
on common pitfalls and how to resolve them. This will be par-
ticularly important for building clinical skills related to HF
management in patients with conditions that were rated uni-
versally low in conﬁdence (i.e. cancer, cerebrovascular dis-
ease, Alzheimer’s disease, and cachexia.)
Addressing gaps in long-term heart failure
management
More than half of HF readmissions may be preventable with
better discharge planning, patient education, and follow-up
care, yet these components of long-term HF management
are often lacking.15,16
The CORE needs assessment evaluated a spectrum of best
practices related to long-term HF management, including
emerging options for long-term monitoring (e.g.
telemonitoring and home-based care), patient education,
transitions of care, and EOL care.
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Clinicians reported rarely or never discussing several topics
with their patients (e.g. advanced care, the role of the care-
taker, psychological health, prognosis, self-care, sexual activ-
ity, and travel/leisure), while other topics were discussed at
the time of HF diagnosis only (e.g. HF aetiology). These ﬁnd-
ings indicate an ongoing need to build skills related to
effective patient education across a range of topics
throughout the HF treatment continuum.
Regardless of provider type, multiple barriers appeared to
contribute to poor transitions of care for patients with HF.
PCPs and primary care nurses reported low conﬁdence
related to following guidelines, procedures, and identifying
patients who require referring to secondary care. Similarly,
conﬁdence was low among cardiologists and cardiac nurses
regarding the level of care offered to patients moving back
into primary care. To address these, HCPs may beneﬁt from
practical advice about implementing guidelines around care
transitions, while interactive exercises may help to build skills
around recognizing which patients are most likely to beneﬁt
from being moved into secondary care.
The majority of HCPs failed to identify many of the clinical
signs that indicate that a patient may beneﬁt from EOL care,
suggesting missed opportunities in clinical practice. To
address this gap, all HCP cohorts would beneﬁt from
exercises that explore the clinical signs of end-stage HF and
highlight the rationale for EOL care.
Study limitations
Limitations associated with the design of the CORE Needs
Assessment Survey include the lack of a focus group for
preliminary testing and instrument validation, the online
format of administration, the potential for selection bias
among respondents, and the relatively small number of
respondents from widely disparate health systems. Practice
patterns were measured against the 2012 ESC HF guide-
lines, which have since been updated.4 Further, the CORE
Needs Assessment Survey was not designed to detect insti-
tutional or systematic barriers to optimal HF care. Where
discrepancies between guideline recommendations and
clinical practice were identiﬁed, the extent to which health
system protocols, local standards of care, legal restrictions,
time constraints, and other issues contributed to these
differences is not clear.
Clinical implications
In summary, the CORE Needs Assessment Survey identiﬁed
multiple knowledge and conﬁdence gaps that are shared
across members of the HF care team, as well as those
that are unique to cardiologists, PCPs, cardiac nurses,
and primary care nurses involved in the management of
patients with HF. These data can inform future educa-
tional initiatives aimed to support improved patient out-
comes through enhanced delivery of evidence-based HF
care.
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